Gene-editing Therapy for ATTR Shows Promise in Preclinical Study

Gene-editing Therapy for ATTR Shows Promise in Preclinical Study

293454

Gene-editing Therapy for ATTR Shows Promise in Preclinical Study

Precision BioScience’s gene-editing therapy for transthyretin amyloidosis (ATTR), a group of disorders that also encompasses familial amyloid polyneuropathy (FAP), shows therapeutic potential in a preclinical study. Data from the study will be presented by Jenny A. Greig, PhD, senior director of the Gene Therapy Program at the Perelman School of Medicine, University of Pennsylvania, in the poster (No. 497) titled “Translation of an AAV-delivered gene editing approach for transthyretin amyloidosis from mice to nonhuman primates,”…

You must be logged in to read/download the full post.